FULC
Fulcrum Therapeutics, Inc.
Biotechnology
Market Cap$372M
5Y Perf.-65.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FULC vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
FULC vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FULC | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $372M | $2.57B |
| Revenue (TTM) | $0.00 | $669M |
| Net Income (TTM) | $-76M | $-609M |
| Gross Margin | — | 83.6% |
| Operating Margin | — | -83.9% |
| Total Debt | $6M | $1.28B |
| Cash & Equiv. | $198M | $434M |
FULC vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FULC
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Fulcrum Therapeutic… (FULC) | 100 | 34.6 | -65.4% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FULC vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FULC leads in 3 of 5 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
FULC
Fulcrum Therapeutics, Inc.
The Income Pick
FULC carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.40
- -49.0% 10Y total return vs RARE's -59.4%
- Lower volatility, beta 1.40, Low D/E 1.8%, current ratio 27.40x
Best for: income & stability and long-term compounding
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Play
RARE is the clearest fit if your priority is growth exposure.
- Rev growth 20.1%, EPS growth 7.3%, 3Y rev CAGR 22.8%
- 20.1% revenue growth vs FULC's -100.0%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RARE | 20.1% revenue growth vs FULC's -100.0% |
| Stability / Safety | FULC | Beta 1.40 vs RARE's 1.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FULC | +35.7% vs RARE's -21.8% |
| Efficiency (ROA) | FULC | -26.3% ROA vs RARE's -45.8%, ROIC -36.2% vs -89.4% |
FULC vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FULC vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFULCLAGGINGRARE
RAREUltragenyx Pharmaceut…
0leads
FULCFulcrum Therapeutics,…
4leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FULC1/1
Valuation MetricsMultiples, price ratios, and targets
FULC1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FULC6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
FULC5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FULC leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RARE and FULC operate at a comparable scale, with $669M and $0 in trailing revenue.
| Metric | FULCFulcrum Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $669M |
| EBITDAEarnings before interest/tax | -$86M | -$536M |
| Net IncomeAfter-tax profit | -$76M | -$609M |
| Free Cash FlowCash after capex | -$64M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | -83.9% |
| Net MarginNet income ÷ Revenue | — | -91.0% |
| FCF MarginFCF ÷ Revenue | — | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +10.7% | -17.2% |
FULC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
FULC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | FULCFulcrum Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $372M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $181M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -5.83x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.82x |
| Price / BookPrice ÷ Book value/share | 1.25x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
FULC leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
FULC leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
FULC delivers a -27.8% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs FULC's 3/9, reflecting mixed financial health.
| Metric | FULCFulcrum Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -27.8% | -6.1% |
| ROA (TTM)Return on assets | -26.3% | -45.8% |
| ROICReturn on invested capital | -36.2% | -89.4% |
| ROCEReturn on capital employed | -28.1% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$191M | $842M |
| Cash & Equiv.Liquid assets | $198M | $434M |
| Total DebtShort + long-term debt | $6M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
FULC leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
FULC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FULC five years ago would be worth $6,565 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, FULC leads with a +35.7% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors FULC at 30.7% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | FULCFulcrum Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -37.0% | +10.7% |
| 1-Year ReturnPast 12 months | +35.7% | -21.8% |
| 3-Year ReturnCumulative with dividends | +123.4% | -44.5% |
| 5-Year ReturnCumulative with dividends | -34.4% | -77.2% |
| 10-Year ReturnCumulative with dividends | -49.0% | -59.4% |
| CAGR (3Y)Annualised 3-year return | +30.7% | -17.8% |
FULC leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — FULC and RARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
FULC is the less volatile stock with a 1.40 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 61.7% from its 52-week high vs FULC's 43.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FULCFulcrum Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.40x | 1.42x |
| 52-Week HighHighest price in past year | $15.74 | $42.37 |
| 52-Week LowLowest price in past year | $4.78 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +43.7% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 42.0 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 990K | 1.8M |
Evenly matched — FULC and RARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates FULC as "Buy" and RARE as "Buy". Consensus price targets imply 200.4% upside for FULC (target: $21) vs 97.1% for RARE (target: $52).
| Metric | FULCFulcrum Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $20.67 | $51.50 |
| # AnalystsCovering analysts | 16 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FULC leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallFulcrum Therapeutics, Inc. (FULC)Leads 4 of 6 categories
Loading custom metrics...
FULC vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FULC or RARE a better buy right now?
For growth investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). Analysts rate Fulcrum Therapeutics, Inc. (FULC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FULC or RARE?
Over the past 5 years, Fulcrum Therapeutics, Inc.
(FULC) delivered a total return of -34. 4%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: FULC returned -49. 0% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FULC or RARE?
By beta (market sensitivity over 5 years), Fulcrum Therapeutics, Inc.
(FULC) is the lower-risk stock at 1. 40β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 1% more volatile than FULC relative to the S&P 500.
04Which is growing faster — FULC or RARE?
By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.
(RARE) is pulling ahead at 20. 1% versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -637. 5% for Fulcrum Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FULC or RARE?
Fulcrum Therapeutics, Inc.
(FULC) is the more profitable company, earning 0. 0% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FULC leads at 0. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FULC or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is FULC or RARE better for a retirement portfolio?
For long-horizon retirement investors, Fulcrum Therapeutics, Inc.
(FULC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (FULC: -49. 0%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FULC and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FULC is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(FULC: -100.0% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.